Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting
Abstract Background Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from clinical trial data. Cariprazine has previously demonstrated a favor...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Annals of General Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12991-024-00542-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571434643226624 |
|---|---|
| author | Christoph U. Correll Andrew J. Cutler François Laliberté Guillaume Germain Sean D. MacKnight Julien Boudreau Sally W. Wade Nadia Nabulsi Huy-Binh Nguyen Mousam Parikh |
| author_facet | Christoph U. Correll Andrew J. Cutler François Laliberté Guillaume Germain Sean D. MacKnight Julien Boudreau Sally W. Wade Nadia Nabulsi Huy-Binh Nguyen Mousam Parikh |
| author_sort | Christoph U. Correll |
| collection | DOAJ |
| description | Abstract Background Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from clinical trial data. Cariprazine has previously demonstrated a favorable safety and tolerability profile in clinical trials. Here, we evaluated the effects of cariprazine on body weight and blood pressure for bipolar I disorder (BP-I), schizophrenia, or as adjunctive treatment for major depressive disorder (MDD) using real-world data. Methods Symphony Health’s Integrated Dataverse® with electronic medical record access (3/1/2015–10/31/2018) was used to identify adults (≥ 18 years) diagnosed with BP-I depression, BP-I mania/mixed, schizophrenia, or MDD, with ≥ 2 cariprazine dispensings (first dispensing = index) and continuous clinical activity for ≥ 12 months pre-index (baseline) and ≥ 3 months post-index. The on-treatment period spanned from index to cariprazine discontinuation, exposure to another atypical or long-acting injectable antipsychotic, or end of clinical activity/data availability. Outcomes included estimated annual linear trajectories for weight, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) during baseline and on treatment. Changes were estimated using linear mixed-effects models fitted over measurements pre-index and on treatment; 95% CIs were derived from nonparametric bootstrap procedures. Results The body weight analysis included 612 patients (BP-I, n = 331 [BP-I depression, n = 172; BP-I mania/mixed, n = 159]; schizophrenia, n = 75; MDD, n = 206). The mean patient age was 43.4 years, 75.2% were female, and the mean (SD) on-treatment period was 219 (185) days. Among patients with measurements before and during cariprazine treatment, estimated annual weight trajectories were + 3.55 (95% CI 2.38, 4.59) kg/year before cariprazine initiation and + 0.91 (− 1.17, 2.82) kg/year during cariprazine treatment. Additionally, annual linear trajectories evaluated across the on-treatment period were + 0.31 (− 0.42, 1.01) kg/m2/year for BMI, − 2.38 (− 4.27, − 0.76) mmHg/year for SBP, and − 0.57 (− 1.75, 0.61) mmHg/year for DBP. Conclusion In this real-world analysis, cariprazine was associated with an estimated weight gain of + 0.91 kg/year and had minimal impact on BMI and blood pressure when evaluated up to 12 months. |
| format | Article |
| id | doaj-art-37c7fbcf62334082b8fd2044eb5d027c |
| institution | Kabale University |
| issn | 1744-859X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Annals of General Psychiatry |
| spelling | doaj-art-37c7fbcf62334082b8fd2044eb5d027c2025-02-02T12:35:44ZengBMCAnnals of General Psychiatry1744-859X2025-01-0124111210.1186/s12991-024-00542-wImpact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world settingChristoph U. Correll0Andrew J. Cutler1François Laliberté2Guillaume Germain3Sean D. MacKnight4Julien Boudreau5Sally W. Wade6Nadia Nabulsi7Huy-Binh Nguyen8Mousam Parikh9Department of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellSUNY Upstate Medical UniversityGroupe d’analyse, LtéeGroupe d’analyse, LtéeGroupe d’analyse, LtéeGroupe d’analyse, LtéeWade Outcomes Research and ConsultingAbbVieAbbVieAbbVieAbstract Background Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from clinical trial data. Cariprazine has previously demonstrated a favorable safety and tolerability profile in clinical trials. Here, we evaluated the effects of cariprazine on body weight and blood pressure for bipolar I disorder (BP-I), schizophrenia, or as adjunctive treatment for major depressive disorder (MDD) using real-world data. Methods Symphony Health’s Integrated Dataverse® with electronic medical record access (3/1/2015–10/31/2018) was used to identify adults (≥ 18 years) diagnosed with BP-I depression, BP-I mania/mixed, schizophrenia, or MDD, with ≥ 2 cariprazine dispensings (first dispensing = index) and continuous clinical activity for ≥ 12 months pre-index (baseline) and ≥ 3 months post-index. The on-treatment period spanned from index to cariprazine discontinuation, exposure to another atypical or long-acting injectable antipsychotic, or end of clinical activity/data availability. Outcomes included estimated annual linear trajectories for weight, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) during baseline and on treatment. Changes were estimated using linear mixed-effects models fitted over measurements pre-index and on treatment; 95% CIs were derived from nonparametric bootstrap procedures. Results The body weight analysis included 612 patients (BP-I, n = 331 [BP-I depression, n = 172; BP-I mania/mixed, n = 159]; schizophrenia, n = 75; MDD, n = 206). The mean patient age was 43.4 years, 75.2% were female, and the mean (SD) on-treatment period was 219 (185) days. Among patients with measurements before and during cariprazine treatment, estimated annual weight trajectories were + 3.55 (95% CI 2.38, 4.59) kg/year before cariprazine initiation and + 0.91 (− 1.17, 2.82) kg/year during cariprazine treatment. Additionally, annual linear trajectories evaluated across the on-treatment period were + 0.31 (− 0.42, 1.01) kg/m2/year for BMI, − 2.38 (− 4.27, − 0.76) mmHg/year for SBP, and − 0.57 (− 1.75, 0.61) mmHg/year for DBP. Conclusion In this real-world analysis, cariprazine was associated with an estimated weight gain of + 0.91 kg/year and had minimal impact on BMI and blood pressure when evaluated up to 12 months.https://doi.org/10.1186/s12991-024-00542-wBipolar I disorderMajor depressive disorderSchizophreniaCariprazineAtypical antipsychoticsWeight gain |
| spellingShingle | Christoph U. Correll Andrew J. Cutler François Laliberté Guillaume Germain Sean D. MacKnight Julien Boudreau Sally W. Wade Nadia Nabulsi Huy-Binh Nguyen Mousam Parikh Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting Annals of General Psychiatry Bipolar I disorder Major depressive disorder Schizophrenia Cariprazine Atypical antipsychotics Weight gain |
| title | Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting |
| title_full | Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting |
| title_fullStr | Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting |
| title_full_unstemmed | Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting |
| title_short | Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting |
| title_sort | impact of cariprazine on body weight and blood pressure among adults with bipolar i disorder schizophrenia or major depressive disorder in a real world setting |
| topic | Bipolar I disorder Major depressive disorder Schizophrenia Cariprazine Atypical antipsychotics Weight gain |
| url | https://doi.org/10.1186/s12991-024-00542-w |
| work_keys_str_mv | AT christophucorrell impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT andrewjcutler impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT francoislaliberte impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT guillaumegermain impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT seandmacknight impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT julienboudreau impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT sallywwade impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT nadianabulsi impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT huybinhnguyen impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting AT mousamparikh impactofcariprazineonbodyweightandbloodpressureamongadultswithbipolaridisorderschizophreniaormajordepressivedisorderinarealworldsetting |